[Postmenopausal malignant transformation of extragenital endometriosis. A case report].
Malignant transformation of endometriosis is a rare event. The ovaries are the most common sites reported in the literature. Postmenopausal cancer arising in extragenital endometriosis is still more exceptional. Hormone replacement therapy and perhaps, to a lesser extent, Tamoxifen could be risk factors for the malignant transformation of endometriosis. We herein report the case of a patient who has developed, after 11 years of hormone replacement therapy, an extragenital endometrioid carcinoma in the vesico-uterine pouch.
Fat
B Chung
BC
Service de gynécologie-obstétrique, centre hospitalier de Belfort-Montbéliard, 14, rue de Mulhouse, 90016 Belfort cedex, France.
Terzibachian
J-J
JJ
Govyadovskiy
A
A
Grisey
A
A
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018269:Carcinoma, Endometrioid / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D002471:Cell Transformation, Neoplastic; D004715:Endometriosis / Q000473:pathology* / Q000601:surgery; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D017698:Postmenopause; D013629:Tamoxifen / Q000009:adverse effects*; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery
D000970:Antineoplastic Agents; D013629:Tamoxifen